Research programme: tolerogenic vaccines - Idogen

Drug Profile

Research programme: tolerogenic vaccines - Idogen

Latest Information Update: 22 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Idogen; Lund University
  • Class Dendritic cell vaccines
  • Mechanism of Action Factor VIII inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia A; Renal transplant rejection

Most Recent Events

  • 11 May 2017 Preclinical trials in Renal transplant rejection (Prevention) in Sweden (IV)
  • 11 May 2017 Idogen plans a phase I/IIa trial for Renal transplant rejection
  • 23 Mar 2017 Idogen receives patent allowance for its tolerogenic vaccine technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top